Opposing roles of PARP-1 in MMP-9 and TIMP-2 expression and mast cell degranulation in dyslipidemic dilated cardiomyopathy

Cardiovascular Pathology

Volumn 20, Issue 2, 2011, Pages

  Hans, Chetan P ^a   Feng, Yumei ^a,b   Naura, Amarjit S ^a   Troxclair, Dana ^a   Zerfaoui, Mourad ^a   Siddiqui, Danish ^a   Jihang, Ju ^a   Kim, Hogyoung ^a   Kaye, Alan D ^a   Matrougui, Khalid ^b   Lazartigues, Eric ^a   Boulares, A Hamid ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell death; Echocardiography; Mast cell; Matrix metalloproteinases; PARP

Indexed keywords

APOLIPOPROTEIN E; COLLAGEN; GELATINASE B; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL NUCLEUS; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DILATATION; DYSLIPIDEMIC DILATED CARDIOMYOPATHY; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; GENE DELETION; GENETIC ASSOCIATION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE SEPTUM; HEMODYNAMIC PARAMETERS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIPID DIET; MAST CELL DEGRANULATION; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARDIOMYOPATHY, DILATED; CELL DEGRANULATION; DIET, ATHEROGENIC; DYSLIPIDEMIAS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MAST CELLS; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; POLY(ADP-RIBOSE) POLYMERASES; POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFECTION;

EID: 79551585394     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carpath.2010.03.007     Document Type: Article

References (41)

1. Carreno JE, Apablaza F, Ocaranza MP, and Jalil JE Cardiac hypertrophy: molecular and cellular events Rev Esp Cardiol 59 5 2006 473 486
2. Gupta S, Das B, and Sen S Cardiac hypertrophy: mechanisms and therapeutic opportunities Antioxid Redox Signal 9 6 2007 623 652
3. Spinale FG Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function Physiol Rev 87 4 2007 1285 1342
4. Haudek SB, Taffet GE, Schneider MD, and Mann DL TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways J Clin Invest 117 9 2007 2692 2701
5. Pillai JB, Gupta M, Rajamohan SB, Lang R, Raman J, and Gupta MP Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy Am J Physiol Heart Circ Physiol 291 4 2006 H1545 H1553
6. Balakumar P, and Singh M Possible role of poly(ADP-ribose) polymerase in pathological and physiological cardiac hypertrophy Methods Find Exp Clin Pharmacol 28 10 2006 683 689 (Pubitemid 46230792)
7. Chalmers AJ Poly(ADP-ribose) polymerase-1 and ionizing radiation: sensor, signaller and therapeutic target Clin Oncol (R Coll Radiol) 16 1 2004 29 39
8. Hans CP, Feng Y, Naura AS, Zerfaoui M, Rezk BM, Xia H, Kaye AD, Matrougui K, Lazartigues E, and Boulares AH Protective effects of PARP-1 knockout on dyslipidemia-induced autonomic and vascular dysfunction in ApoE mice: effects on eNOS and oxidative stress PLoS One 4 10 2009 e7430
9. Oumouna-Benachour K, Hans CP, Suzuki Y, Naura A, Datta R, Belmadani S, Fallon K, Woods C, and Boulares AH Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death Circulation 115 18 2007 2442 2450
10. Pacher P, and Szabo C. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors Cardiovasc Drug Rev 25 3 2007 235 260
11. Hans CP, Zerfaoui M, Naura AS, Catling A, and Boulares AH Differential effects of PARP inhibition on vascular cell survival and ACAT-1 expression favouring atherosclerotic plaque stability Cardiovasc Res 78 3 2008 429 439
12. von Lukowicz T, Hassa PO, Lohmann C, Boren J, Braunersreuther V, Mach F, Odermatt B, Gersbach M, Camici GG, Stahli BE, Tanner FC, Hottiger MO, Luscher TF, and Matter CM PARP1 is required for adhesion molecule expression in atherogenesis Cardiovasc Res 78 1 2008 158 166
13. Zervoudaki A, Economou E, Stefanadis C, Pitsavos C, Tsioufis K, Aggeli C, Vasiliadou K, Toutouza M, and Toutouzas P Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment J Hum Hypertens 17 2 2003 119 124
14. Frantz S, Stork S, Michels K, Eigenthaler M, Ertl G, Bauersachs J, and Angermann CE Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality Eur J Heart Fail 10 4 2008 388 395
15. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture Physiol Rev 85 1 2005 1 31
16. Hammani K, Blakis A, Morsette D, Bowcock AM, Schmutte C, Henriet P, and DeClerck YA. Structure and characterization of the human tissue inhibitor of metalloproteinases-2 gene J Biol Chem 271 41 1996 25498 25505 (Pubitemid 26337925)
17. Zhong ZD, Hammani K, Bae WS, and DeClerck YA NF-Y and Sp1 cooperate for the transcriptional activation and cAMP response of human tissue inhibitor of metalloproteinases-2 J Biol Chem 275 24 2000 18602 18610
18. Claycomb WC, Lanson NA, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A, and Izzo NJ. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte Proc Natl Acad Sci U S A 95 6 1998 2979 2984
19. Murakami S, Kondo-Ohta Y, and Tomisawa K Improvement in cholesterol metabolism in mice given chronic treatment of taurine and fed a high-fat diet Life Sci 64 1 1998 83 91
20. Takasaki Y Serum lipid levels and factors affecting atherogenic index in Japanese children J Physiol Anthropol Appl Hum Sci 24 4 2005 511 515
21. Yamashita C, Hayashi T, Mori T, Tazawa N, Kwak CJ, Nakano D, Sohmiya K, Okada Y, Kitaura Y, and Matsumura Y. Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice Hypertens Res 30 12 2007 1219 1230
22. Ainscough JF, Drinkhill MJ, Sedo A, Turner NA, Brooke DA, Balmforth AJ, and Ball SG Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction Cardiovasc Res 81 3 2009 592 600
23. Polizio AH, Balestrasse KB, Yannarelli GG, Noriega GO, Gorzalczany S, Taira C, and Tomaro ML Angiotensin II regulates cardiac hypertrophy via oxidative stress but not antioxidant enzyme activities in experimental renovascular hypertension Hypertens Res 31 2 2008 325 334
24. Hartley CJ, Reddy AK, Madala S, Martin-McNulty B, Vergona R, Sullivan ME, Halks-Miller M, Taffet GE, Michael LH, Entman ML, and Wang YX Hemodynamic changes in apolipoprotein E-knockout mice Am J Physiol Heart Circ Physiol 279 5 2000 H2326 H2334
25. Wang YX Cardiovascular functional phenotypes and pharmacological responses in apolipoprotein E deficient mice Neurobiol Aging 26 3 2005 309 316
26. Bartha E, Kiss GN, Kalman E, Kulcsar G, Kalai T, Hideg K, Habon T, Sumegi B, Toth K, and Halmosi R Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure J Cardiovasc Pharmacol 52 3 2008 253 261
27. Bartha E, Solti I, Kereskai L, Lantos J, Plozer E, Magyar K, Szabados E, Kalai T, Hideg K, Halmosi R, Sumegi B, and Toth K PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats Cardiovasc Res 2009
28. Hutchinson KR, Stewart JA, and Lucchesi PA Extracellular matrix remodeling during the progression of volume overload-induced heart failure J Mol Cell Cardiol 2009
29. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, and Zile MR Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease Circulation 113 17 2006 2089 2096
30. Malemud CJ Matrix metalloproteinases (MMPs) in health and disease: an overview Front Biosci 11 2006 1696 1701
31. Nagase H, Visse R, and Murphy G Structure and function of matrix metalloproteinases and TIMPs Cardiovasc Res 69 3 2006 562 573
32. Stetler-Stevenson WG, and Seo D-W TIMP-2: an endogenous inhibitor of angiogenesis Trends Mol Med 11 3 2005 97 103
33. Loftus IM, Naylor AR, Bell PR, and Thompson MM Matrix metalloproteinases and atherosclerotic plaque instability Br J Surg 89 6 2002 680 694
34. Seo D-W, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, Wei B-Y, and Stetler-Stevenson WG TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism Cell 114 2 2003 171 180
35. Anan F, Yonemochi H, Masaki T, Takahashi N, Fukunaga N, Teshima Y, Iwao T, Kaneda K, Eshima N, Saikawa T, and Yoshimatsu H High-density lipoprotein cholesterol and insulin resistance are independent and additive markers of left ventricular hypertrophy in essential hypertension Hypertens Res 30 2 2007 125 131
36. Brower GL, Chancey AL, Thanigaraj S, Matsubara BB, and Janicki JS Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity Am J Physiol Heart Circ Physiol 283 2 2002 H518 525
37. Janicki JS, Brower GL, Gardner JD, Forman MF, Stewart JA, Murray DB, and Chancey AL Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload Cardiovasc Res 69 3 2006 657 665
38. Balakumar P, Singh AP, Ganti SS, Krishan P, Ramasamy S, and Singh M Resident cardiac mast cells: are they the major culprit in the pathogenesis of cardiac hypertrophy? Basic Clin Pharmacol Toxicol 102 1 2008 5 9
39. Chancey AL, Brower GL, and Janicki JS Cardiac mast cell-mediated activation of gelatinase and alteration of ventricular diastolic function Am J Physiol Heart Circ Physiol 282 6 2002 H2152 H2158
40. Cuzzocrea S Shock, inflammation and PARP Pharmacol Res 52 1 2005 72 82
41. Zhang QY, Ge JB, Chen JZ, Zhu JH, Zhang LH, Lau CP, and Tse HF Mast cell contributes to cardiomyocyte apoptosis after coronary microembolization J Histochem Cytochem 54 5 2006 515 523